Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SMARCB1
REST API REST API
Homo sapiens
SMARCB1 is differentially expressed in 226 experiments: 102 organism parts: cerebellum, ovary, ... (100 more);, 163 disease states: normal, Burkitt's lymphoma, ... (161 more);, 72 cell types 314 cell lines 26 compound treatments and 74 other conditions.
Synonyms BAF47, hSNFS, SNF5L1, Snr1, RDT, Sfh1p, Ini1
Orthologs SNF5_BOVIN (Bos taurus)   smarcb1b (Danio rerio)   Q4KLI0_RAT (Rattus norvegicus)   SNF5_CHICK (Gallus gallus)   ENSCING00000009008 (Ciona intestinalis)   smarcb1a (Danio rerio)   Smarcb1 (Mus musculus)   Snr1 (Drosophila melanogaster)   SFH1 (Saccharomyces cerevisiae)   smarcb1 (Xenopus laevis)   SMARCB1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, DNA integration, negative regulation of cell proliferation, chromatin remodeling complex, nuclear chromosome, cell differentiation, soluble fraction, cell cycle, positive regulation of transcription from RNA polymerase II promoter, transcription coactivator activity, nucleus, chromatin remodeling, nervous system development, nucleoplasm, regulation of transcription from RNA polymerase II promoter, nucleolus, nBAF complex, npBAF complex, Tat protein binding, SWI/SNF complex, positive regulation by host of viral transcription, blastocyst hatching, XY body, blastocyst development, interspecies interaction between organisms, p53 binding, nucleosome disassembly, retroviral genome replication, positive regulation of sequence-specific DNA binding transcription factor activity
InterPro Term SNF5, SWI_SNF_chromatin_remodel_cplx
UniProt Accession Q17S11, B5MCL5, C9JTA6, Q12824, Q86WI6
Gene-Disease Assocation SCHWANNOMATOSIS, RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1
Search EB-eye ENSG00000099956
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-GEOD-22541, E-MEXP-1251, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-4717, ... (40 experiments)

Factor Value U/D Experiments
HL-60
2
E-MTAB-37, E-GEOD-24147
SNU16
2
E-MTAB-37, E-GEOD-15460
A549
2
E-GEOD-3202, E-GEOD-6013
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-3529, E-GEOD-5823
MDAMB453
2
E-MTAB-37, E-MTAB-62
308 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (34 experiments)

Factor Value U/D Experiments
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-26672
mononuclear
2
E-GEOD-13987, E-GEOD-26672
activated natural killer cell (supplemented for IL2 for 2 hours)
1
E-TABM-702
ovarian cancer
1
E-GEOD-21154
dendritic cell
1
E-MEXP-2019
66 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-22148, ... (45 experiments)

Factor Value U/D Experiments
Burkitt's lymphoma
3
E-MTAB-37, E-GEOD-1880, E-GEOD-96
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
prostate carcinoma
3
E-MEXP-2034, E-GEOD-96, E-MTAB-62
lung adenocarcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-2514
multiple myeloma
1
2
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
Partially decidualised
1
E-MTAB-680
157 more value(s).


Compound treatment

studied in E-GEOD-15205, E-GEOD-5824, E-TABM-868, E-GEOD-6462, E-MEXP-1958, ... (15 experiments)

Factor Value U/D Experiments
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
unknown
1
E-GEOD-7307
HMB-PP (phosphoantigen)
1
1
E-MEXP-1601
5-fluorouridine
1
E-GEOD-995
ethanol
1
E-MEXP-2241
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
20 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-GEOD-2666, E-GEOD-4667, ... (6 experiments)

Disease staging
studied in E-GEOD-19743, E-GEOD-22541, E-GEOD-22148, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-1643, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4006, E-MEXP-563

Genotype
studied in E-TABM-1029, E-MEXP-1437, E-GEOD-3494, E-TABM-321, E-GEOD-18005, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-GEOD-7011, E-GEOD-20540, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194, E-GEOD-21653, E-GEOD-20559, E-TABM-276 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-26, ... (27 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-MEXP-561

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, E-MEXP-1403

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-3494, E-GEOD-22541, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.246 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM